Document is current
Any future updates will be listed below
-
Authors
Rubin, Jaime L.
McKinnon, Craig
Pedra, Gabriel Ghizzi
Morgan, Devon A.
Zweig, Kimberly
Liou, Theodore G.
-
Funding
Funding for this research was provided by:
Vertex Pharmaceuticals
- License Information
-
More Information
Article History
Received: 9 April 2025
Accepted: 30 May 2025
First Online: 11 July 2025
Declarations
:
: Jaime L. Rubin, Craig McKinnon and Gabriel Ghizzi Pedra are employees of Vertex Pharmaceuticals Incorporated and may own stocks/stock options in the company. Devon A. Morgan and Kimberly Zweig have received consultancy fees from Vertex Pharmaceuticals Incorporated. Theodore G. Liou is an employee of the University of Utah which received funding from Vertex for this project. Theodore G. Liou is supported by the NIH/NHLBI (R01 HL125520), the Cystic Fibrosis Foundation, Bethesda, MD (grants CC-132-16AD, LIOU13A0, LIOU14Y0, and LIOU14Y4), the Ben B. and Iris M. Margolis Family Foundation of Utah, and the Claudia Ruth Goodrich Stevens Endowment Fund.
: This is a comprehensive narrative literature review and peer-reviewed articles were identified using PubMed. Additionally, a secondary analysis was conducted using recent longitudinal data from the U.S. CFFPR. The U.S. CFFPR collects prospective data on consenting people with CF. Internal Review Board (IRB) approval was not required.
